NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1.
AP endonuclease 1 (APE1) is a multifaceted protein with essential roles in DNA repair and transcriptional regulation. APE1 (ref-1) activates many transcription factors (TF), including AP-1 and NF-κB. While the mechanism of APE1 redox activity remains unknown, it may involve reduction of an oxidized Cys in the TF DNA-binding domain. Several small molecules inhibit APE1-mediated TF activation, including the quinone derivative E3330. It has been proposed some inhibitors bind near C65, a residue suggested to be important for TF activation, but the binding site has not been determined for any inhibitor. Remarkably, NMR and molecular docking studies here reveal E3330 binds in the DNA repair active site of APE1, far removed from C65. Accordingly, AP endonuclease activity is substantially inhibited by E3330 (100 μM), suggesting that E3330 may not selectively inhibit APE1 redox activity in cells, in contrast with previous proposals. A naphthoquinone analogue of E3330, RN7-60, binds a site removed from both C65 and the repair active site. While a detailed understanding of how these inhibitors work requires further studies into the mechanism of redox activity, our results do not support proposals that E3330 binds selectively (and slowly) to locally unfolded APE1 or that E3330 promotes formation of disulfide bonds in APE1. Rather, we suggest E3330 may suppress a conformational change needed for redox activity, disrupt productive APE1-TF binding, or block the proposed redox chaperone activity of APE1. Our results provide the first structural information for any APE1 redox inhibitor and could facilitate development of improved inhibitors for research and perhaps clinical purposes.
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Brittney A
BA
Manvilla
Orrette
O
Wauchope
Katherine L
KL
Seley-Radtke
Alexander C
AC
Drohat
D000818:Animals; D016227:Benzoquinones / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008689:Methacrylates / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D009285:Naphthoquinones / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology; D010084:Oxidation-Reduction / Q000187:drug effects; D011422:Propionates / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects
C569501:3-(3-chloro-1,4-naphthoquinon-2-yl)-2-methylpropenoic acid; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D008689:Methacrylates; D009285:Naphthoquinones; D011422:Propionates; C075569:E 3330; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase